Disclaimer: We may earn a commission if you make any purchase by clicking our links. Please see our detailed guide here.

Follow us on:

Standigm Partners With Excelra for GOSTAR To Enhance Its AI-Driven Drug Discovery Process

Join the Opinion Leaders Network

Join the Techgenyz Opinion Leaders Network today and become part of a vibrant community of change-makers. Together, we can create a brighter future by shaping opinions, driving conversations, and transforming ideas into reality.

Excelra, a global data science and data analytics company, today announced its collaboration with Standigm Inc., a company using artificial intelligence (AI) technology for drug discovery and development.

Under the agreement, Excelra will provide its small molecule medicinal chemistry intelligence platform GOSTAR to Standigm Inc. GOSTAR provides comprehensive information encompassing over 8 million compounds, manually curated from 3 million patents and 200,000 journal articles.

The database contains over 28 million SAR-associated data points. The well-structured relational database can be utilized for diverse applications across different stages of the drug discovery and development lifecycle and aids in target validation, hit Identification, early lead Identification, and optimization.

Hanjo Kim, Platform Team Leader, Standigm Inc., said: “For an AI-based drug discovery company, high-quality SAR data is of great importance. Our platform technologies, Standigm BEST, Standigm ASK, and Standigm Insight integrate lots of data to generate innovative ideas including finding novel targets, developing predictive models, and designing novel lead series compounds. I expect GOSTAR can help this process.”

Raveendra Dayam, Director of Chemistry Services, Excelra said: “GOSTAR is the largest source for experimentally determined interactions of millions of small molecules with most of the potential drug targets. The platform provides a comprehensive overview of millions of compounds, linking chemical structure to biological, pharmacological and therapeutic activities. These datasets are core to the AI/ML driven drug discovery programs that support rapid discovery of novel drug candidates.”

About Standigm

Standigm Inc. is an Artificial Intelligence (AI)-driven drug discovery company. Applying its own innovative AI to the real world, Standigm Inc. eliminates uncertainty in the drug discovery process and develops therapeutic candidates that are primed for success. Pursuing a full-stack, AI-driven industrializing drug discovery, Standigm Inc. has achieved the automation of molecular design workflow (Dark MolFactory ) and the automation effort has been expanding to the whole drug discovery process based on Standigm AI platforms, including Standigm ASK (Target discovery), Standigm BEST (Lead selection), and Standigm Insight (Drug repurposing).

Visit www.standigm.com

Contact : business@standigm.com

About Excelra: Excelra’s data science and data analytics solutions empower innovation in life sciences.

The Excelra Edge comes from a seamless amalgamation of proprietary data assets, domain expertise, and data science, to accelerate drug discovery and development. www.excelra.com

Partner With Us

Digital advertising offers a way for your business to reach out and make much-needed connections with your audience in a meaningful way. Advertising on Techgenyz will help you build brand awareness, increase website traffic, generate qualified leads, and grow your business.

Join 10,000+ Fellow Readers

Get Techgenyz’s roundup delivered to your inbox curated with the most important for you that keeps you updated about the future tech, mobile, space, gaming, business and more.

Recomended

Find Apps

The Ultimate Hub for Discovering Apps Unlock a world of apps: your ultimate hub for exploring and discovering limitless possibilities for on your every needs.

Power Your Business

Solutions you need to super charge your business and drive growth

More from this topic